Induced Pluripotent Stem Cells Production Market to Grow with a CAGR of 10.44% through 2030
Growing continuous
advancements in biotechnology and genome editing techniques is expected to
drive the Global Induced Pluripotent Stem Cells Production Market in the
forecast period 2026-2030.
According to
TechSci Research report, “Induced Pluripotent Stem Cells Production
Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities,
2030”, the Global Induced Pluripotent Stem Cells Production Market stood at
USD 1.35 Billion in 2024 and is anticipated to grow with a CAGR of 10.44% in the
forecast period through 2030. The induced pluripotent stem cells
(iPSCs) production market is currently experiencing a surge in growth,
primarily due to its expanding therapeutic applications. iPSCs, once considered
a revolutionary discovery in the field of regenerative medicine, are now at the
forefront of research and development efforts to treat a wide range of diseases
and conditions. For conditions
like Duchenne muscular dystrophy, iPSCs have been instrumental in modeling the
disease and testing potential therapies. Researchers are exploring the
possibility of using iPSC-derived muscle cells for transplantation or gene
editing to treat this and other muscular disorders. iPSCs are increasingly used
in cancer research to study disease progression, screen potential anti-cancer
drugs, and understand the underlying genetic and molecular mechanisms of
various cancer types. This application is aiding in the development of more
targeted and effective cancer treatments. iPSCs have shown promise in the
regeneration of damaged spinal cord tissues and nerves, offering hope to
patients with spinal cord injuries and paralysis. This area of research has the
potential to revolutionize rehabilitation and improve the quality of life for
those affected. iPSCs can be
differentiated into various blood cell types, making them valuable for the
treatment of blood disorders such as sickle cell anemia and thalassemia.
Patient-specific iPSC-derived blood cells could replace the need for donor
transplants, reducing the risk of rejection and complications.
The induced
pluripotent stem cells (iPSCs) production market has experienced remarkable
growth, thanks in large part to its pivotal role in drug discovery and toxicity
testing. These versatile cells have revolutionized the pharmaceutical industry
by providing a highly efficient and ethical platform for evaluating drug
candidates, understanding disease mechanisms, and ensuring the safety of novel
compounds. Toxicity testing is another domain where iPSCs are making a
significant impact. Traditional methods of assessing drug toxicity relied on
animal testing and immortalized cell lines, which often led to inaccuracies in
predicting human responses. iPSCs, with their ability to differentiate into
various cell types, enable researchers to create more physiologically relevant
in vitro models of toxicity. These models can be used to assess drug-induced
toxicities on specific organs, such as the liver, heart, and kidneys, providing
valuable data for drug safety evaluation. Additionally, iPSCs allow for the
development of patient-specific toxicity models, addressing the issue of
inter-individual variability in drug responses. By using iPSCs derived from
diverse patient populations, researchers can identify potential toxicities that
may affect certain groups more severely, contributing to safer drug development
and personalized medicine.
Furthermore, the
use of iPSCs in toxicity testing aligns with the growing emphasis on reducing
animal testing and promoting ethical research practices. iPSC-based assays
provide a more humane and ethically acceptable alternative for assessing drug
safety without compromising the quality of data. The synergy between iPSCs and
drug discovery and toxicity testing has also accelerated the development of
innovative technologies and automation in the life sciences industry.
High-throughput screening platforms, robotic systems, and advanced imaging
techniques have been integrated into iPSC-based assays, allowing researchers to
analyze a vast number of compounds and data points simultaneously. This
increased efficiency not only expedites drug discovery but also enhances the
precision and reliability of toxicity assessments. Moreover, the convergence of
iPSCs with other cutting-edge technologies, such as CRISPR-Cas9 gene editing
and organ-on-a-chip systems, is shaping the future of pharmaceutical research.
Researchers can now engineer iPSCs to carry specific genetic mutations
associated with diseases, further refining disease models. Organ-on-a-chip
systems, on the other hand, enable the recreation of complex organ
microenvironments, offering a more comprehensive understanding of drug effects.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Induced Pluripotent Stem Cells Production Market.”
The Global
Induced Pluripotent Stem Cells Production Market is segmented into Process, Product, Application, End-user, regional distribution, and company
Based on the Application, Drug Development and Discovery category shows the fastest growth in the global
market for Induced Pluripotent Stem Cells Production. This is due to
the increasing importance of induced pluripotent stem cells (iPSCs) in the
field of drug development and discovery. iPSCs are a type of stem cell that can
be generated from adult cells and reprogrammed to become pluripotent, meaning
they can differentiate into various cell types in the body. Induced pluripotent
stem cells are widely utilized in disease modelling, which leads to the
invention and discovery of creative treatment strategies. As a result, the
prevalence of diseased diseases is driving the demand for disease knowledge.
Market participants like Evotec SE, for instance, have developed iPSC
infrastructure that acts as a platform for high throughput, reliable, and
reproducible drug screening.
Based on Region, Asia-Pacific region is experiencing rapid growth in the induced pluripotent stem cells (iPSCs) production market. This surge is driven by several factors, including increased government support for healthcare advancements, growing awareness of cell therapies and personalized medicine, and significant investments in stem cell research. Japan, in particular, has made notable strides due to its technological innovations and well-defined regulatory policies governing iPSC research. Similarly, China is witnessing expansion in this field, supported by a favorable environment for human stem cell research and the establishment of multiple stem cell banks. India is also contributing to the market's growth, propelled by a rising prevalence of diseases like cancer and diabetes, which fuels the demand for advanced therapeutic solutions such as stem cell therapy.
Major companies operating
in Global Induced Pluripotent Stem Cells Production Market are:
- Lonza Group
- Axol Biosciences Ltd.
- Evotec SE
- Hitachi Ltd.
- Reprocells Inc.
- Fate Therapeutics.
- Thermo Fisher Scientific, Inc.
- Merck KgaA
- Stemcellsfactory III
- Applied Stemcells Inc.
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The global
Induced Pluripotent Stem Cells Production market is driven by several
compelling factors that collectively contribute to its rapid growth and
innovation in the healthcare industry. First, iPSCs have opened up new avenues
in regenerative medicine. They can be differentiated into various cell types,
making them valuable for treating a wide range of diseases and injuries, such
as heart diseases, Parkinson's, and spinal cord injuries.Also, iPSCs can be
derived from a patient's own cells, reducing the risk of immune rejection when
used for transplantation or cell-based therapies. This personalized approach is
a major driver for the iPSCs market whicjh is creating significant market
growth. Unlike embryonic stem cells, iPSCs do not involve the destruction of
embryos, which has alleviated ethical concerns and regulatory restrictions,
enabling broader research and commercialization. Public and private sectors
have increased funding for stem cell research, including iPSCs, to support
scientific advancements and therapeutic applications. Moreover, advances in reprogramming
techniques, genome editing tools (e.g., CRISPR-Cas9), and bioprocessing
technologies have streamlined iPSCs production and differentiation, making them
more accessible and scalable thereby boosting the market.” said Mr. Karan
Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Induced
Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Process (Manual iPSC Production Process, Automated iPSC
Production Process), By Product (Instruments/ Devices, Automated Platforms,
Consumables & Kits, Services), By Application (Drug Development and
Discovery, Regenerative Medicine, Toxicology Studies, Others), By End-user
(Research & Academic Institutes, Biotechnology & Pharmaceutical
Companies, Hospitals & Clinics) By Region and Competition, 2020-2030F”, has
evaluated the future growth potential of Global Induced Pluripotent Stem Cells
Production Market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions.
Besides, the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Induced Pluripotent
Stem Cells Production Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: sales@techsciresearch.com
Website: www.techsciresearch.com